In August last year the private equity firm bought rehab therapy platform WebPT Inc. Warburg Pincus’ investment alongside the existing majority shareholder, European private equity healthcare specialist ArchiMed, will advance the development and sale of Polyplus’ breakthrough solutions for the delivery of nucleic acids (transfection) for research and the biologics-based production of therapeutic drugs and vaccines. Polyplus develops delivery solutions for nucleic acids, like DNA and RNA, into cells. The company was founded in 2001 as a spinoff from the genetic chemistry laboratory at the University of Strasbourg in eastern France. Illkirch, FRANCE, April 29, 2020 –– Polyplus-transfection® SA (“Polyplus”), a developer of innovative and cost-effective technology used in gene and cell therapy, closed on a major investment from Warburg Pincus, a… ArchiMed and Warburg Pincus will be equal shareholders with the same voting rights. Polyplus develops delivery solutions for nucleic acids, like DNA and RNA, into cells.

The method is used for investigating gene functions, virus production, protein delivery and gene editing. Polyplus-transfection Polyplus-transfection develops, markets and sells solutions for the delivery of nucleic acids in research, bioproduction and therapeutics. All rights reserved. Over four years, Polyplus revenues have increased ten-fold, with ArchiMed holding 90 percent of Polyplus prior to the transaction. We combine Bloomberg’s global leadership in business and financial news and data, with Quintillion Media’s deep expertise in the Indian market and digital news delivery, to provide high quality business news, insights and trends for India’s sophisticated audiences. Polyplus is a strong fit with that thesis, and we believe there is a significant opportunity to build it into the leading solutions platform in the category.”. Warburg Pincus has reached a preliminary agreement to acquire French biotechnology company Polyplus-Transfection SA from investment firm ArchiMed SAS, people with knowledge of the matter said. Polyplus-transfection Polyplus-transfection develops, markets and sells solutions for the delivery of nucleic acids in research, bioproduction and therapeutics. Lyon-based ArchiMed acquired a majority stake in Polyplus in 2016. For more information please visit www.archimed-group.eu, Neil Hunter, neil@ibcomms.agency, +44 (0)20 8943 4685, Gabriel Festoc, gfestoc@polyplus-transfection.com, +33 6 62 22 45 90, Kerrie Cohen, kerrie.cohen@warburgpincus.com, +1 212 878 9207, David Lanchner, dlanchner@lanchner.com, +33 6 33 43 5076, Stéphanie du Ché, stephanie.duche@archimed-group.eu, +33 6 16 36 11 08, Accounting and Tax: PricewaterhouseCoopers LLP. Gaute irure dolor adipisicing elit, sed do eiusmod tempor incididunt ipsum massa sed turpis vulputate tristique urna, nec feugiat lorem ipsum dolor. This acquisition would add to Warburg Pincus’s long list of deals in the health-care technology space.
Bloomberg | Quint is a multiplatform, Indian business and financial news company. Polyplus’ reagents are embedded in the majority of clinical-stage and commercially approved drugs in the rapidly growing gene therapy market.

The firm has more than $54 billion in assets under management.

Kirkland Advises Warburg Pincus on Growth Investment, in Partnership with ArchiMed, in Polyplus, Kirkland Counsels Clearlake on Decision to Acquire Dimora Brands, Kirkland Advises L Catterton and Cholula on $800 Million Sale of Cholula. “Everyone in this deal shares precisely the same vision for the future of Polyplus and this industry.” Added Loïc Kubitza, Partner at ArchiMed, “This investment validates an amazing growth story that’s only becoming more impressive. The firm is headquartered in New York with offices in Amsterdam, Beijing, Berlin, Hong Kong, Houston, London, Luxembourg, Mumbai, Mauritius, San Francisco, São Paulo, Shanghai, and Singapore. Warburg Pincus brings strong healthcare experience and a global network to support innovation and scale-up as Polyplus serves the gene and cell therapy market. Integer vitae ante vitae mauris ipsum massa lorem ipsum dolor ipsum massa sed turpis aliquam eleifend id pulvinar vulputate tristique urna, nec feugiat. To contact the reporters on this story: Myriam Balezou in London at mbalezou@bloomberg.net;Dinesh Nair in London at dnair5@bloomberg.net, To contact the editors responsible for this story: Dinesh Nair at dnair5@bloomberg.net, David Morris (News), {{data.symbol | reutersRICLabelFormat:group.RICS}}, {{ stock | formatPrefix }}{{ stock.netChng | formatNetChange }}.

Warburg Pincus has made an investment in Polyplus, a developer of technology used in gene and cell therapy. Back To Investments ... Warburg Pincus is an experienced partner to management teams seeking to build durable companies with sustainable value. The method is used for investigating gene functions, virus production, protein delivery and gene editing.
Warburg Pincus LLC is a leading global private equity firm focused on growth investing. This acquisition would add to Warburg Pincus’s long list of deals in the health-care technology space. Lyon-based ArchiMed acquired a majority stake in Polyplus in 2016. Representatives for ArchiMed, Polyplus and Warburg Pincus declined to comment. The deal values Polyplus at more than $500 million, said the people, who asked not to be identified because the information is private. Founded in 2001 and based in Strasbourg, France, Polyplus is a leading global supplier of transfection reagents, which are critical inputs used in the manufacturing of cell and gene therapies. Bloomberg | Quint is a multiplatform, Indian business and financial news company. Lyon-based ArchiMed acquired a majority stake in Polyplus in 2016.

Bloomberg the Company & Its Products The Quint. In August last year the private equity firm bought rehab therapy platform WebPT Inc. Warburg Pincus Privacy Notice    Privacy Notice    Personal Data Request    Legal Disclaimer    Forms 20-2 and 21-3. Warburg Pincus is an experienced partner to management teams seeking to build durable companies with sustainable value. The team was supported by transactional associates Guillaume Nivault (Paris) and Dan Clarke (London). Investor Portal | Copyright © 2020 ArchiMed | contact@archimed-group.eu | Legal Notice | Design Agence Sand, An independent investment firm specialized in the Healthcare industries.

Kirkland & Ellis advised Warburg Pincus on its investment in Polyplus-transfection® SA (“Polyplus”), a developer of innovative and cost-effective technology used in gene and cell therapy. Join our. ArchiMed’s investment capacity currently exceeds one billion euros and is potentially twice this amount when including its strategic investment partners. Over the last 20 years, ArchiMed’s leadership team directly managed and invested in over 40 small, medium and large-size healthcare companies throughout the world, with a combined value above five billion euros. Polyplus-transfection’s strengths are 20 years of experience in manufacturing transfection solutions with tailored scientific and regulatory support to accelerate research and clinical development. Since inception, the firm has invested more than $10 billion in more than 150 healthcare companies, including Bausch + Lomb, Sotera Health, and China Biologic Partners (CBPO).